The interaction of mannose binding lectin (MBL) with mannose containing glycopeptides and the resultant potential impact on invasive fungal infection

Medical Mycology

Volumn 46, Issue 6, 2008, Pages 531-539

  Sealy, Patricia I ^a   Garner, Bianca ^a   Swiatlo, Ed ^a   Chapman, Stanley W ^a   Cleary, John D ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

And innate immunity; Dalbavancin; Fungal infection; Mannose binding lection; MBL; Teicoplanin

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; DALBAVANCIN; MANNAN; MANNOSE; MANNOSE BINDING LECTIN; N ACETYLGLUCOSAMINE; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT PROTEIN; SODIUM CHLORIDE; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BAGG ALBINO MOUSE; CANDIDA ALBICANS; COLONY FORMING UNIT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; INVASIVE CANDIDIASIS; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURVIVAL RATE; YEAST;

ANIMALS; ANTI-BACTERIAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; MANNOSE; MANNOSE-BINDING LECTIN; MICE; MICE, INBRED BALB C; PROTEIN BINDING; SURVIVAL; TEICOPLANIN;

CANDIDA; CANDIDA ALBICANS; MURINAE; MUS;

EID: 51649116679     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780801961329     Document Type: Article

References (51)

1. Zaoutis, TE, Argon, J. Chu, J. et al. (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis, 41, pp. 1232-1239.
2. Edmond, MB, Wallace, SE McClish, DK et al. (1999) Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis, 29, pp. 239-244.
3. Wenzel, RP. (1995) Nosocomial candidemia: Risk factors and attributable mortality. Clin Infect Dis, 20, pp. 1531-1534.
4. Vasta, GR, Quesenberry, M., Ahmed, H. and O'Leary, N. (1999) C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev Comp Immunol, 23, pp. 401-420.
5. Lp, W. and Lau, Y. (2004) Role of mannose-binding lectin in the innate defense against Candida albicans: Enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis, 190, pp. 632-640.
6. Turner, MW. (2003) The role of mannose-binding lectin in health and disease. Mol Immunol, 40, pp. 423-429.
7. Jack, DL, Klein, NJ and Malcolm, WT. (2001) Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev, 180, pp. 86-99.
8. van de Wetering, JK, van Golde, LM and Batenburg, JJ. (2004) Collectins: players of the innate immunie sysem. Eur J Biochem, 271, pp. 229-249.
9. Holmskov, U., Thiel, S. and Jensenius, DC. (2003) Collectins and ficolins: Humoral lectins of the innate immune defence. Annu Rev Immunol, 21, pp. 547-578.
10. Somma, S., Gastaldo, L. and Corti, A. (1984) Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother, 26, pp. 917-923.
11. Chen, AY, Zervos, MJ and Vazquez, JA. (2007) Dalbavancin: A novel antimicrobial. Int J Clin Pract, 61, pp. 853-863.
12. Candiani, G., Abbondi, M., Borgonovi, M., Romano, G. and Parenti, F. (1999) In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother, 44, pp. 179-192.
13. Reynolds, PE. (1989) Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis, 8, pp. 943-950.
14. Lillegard, JB, Sim, RB, Thorkildson, P., Gates, MA and Kozel, TR. (2006) Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis, 193, pp. 1589-1597.
15. Mini-PROTEAN® 3 Cell, Instruction Manual Catalog Numbers 165-3301 and 165-3302.
16. SilverSNAP Stain Kit II® Instruction Manual Number 24612.
17. National Committee for Clinical Laboratory Standards (NCCLC) (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard.
18. (2006) Sanquin: Human Mannose binding lectin ELISA kit product information.
19. Peetermans, WE, Hoogeterp, JJ, Hazekamp-van Dokkum, AM, van den Broek, P and Mattie, H. (1990) Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother, 34, pp. 1869-1874.
20. Candiani, G., Abbondi, M., Borgonovi, M., Romano, G. and Parenti, F. J. (1999) In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. Antimicrob Chemother, 44, pp. 179-192.
21. Kaneko, Y., Yanagihara, K. Miyazaki, Y. et al. (2003) Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice. Antimicrob Agents Chemother, 47, pp. 3694-3698.
22. Ghiselli, R., Cirioni, O. Giacometti, A. et al. (2008) Comparative efficacy of topical versus systemic teicoplanin in experimental model of wound infections. J Surg Res, 144, pp. 74-81.
23. Andes, D. and Craig, WA. (2007) In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother, 51, pp. 1633-1642.
24. Walport, MJ. (2001) Advances in immunology: Complement (First of Two Parts). N Eng J Med, 344, pp. 1058-1066.
25. Hoffman, JA, Kafatos, FC, Janeway, CA and Ezekowitz, R. (1999) Phylogenetic perspectives innate immunity. Science, 284, pp. 1313-1318.
26. Suankratay, C., Mold, C. Zhang, Y. et al. (1998) Complement regulation in innate immunity and the acute-phase response: Inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein. Clin Exp Immunol, 113, pp. 353-359.
27. Hill, AVS. (2001) Human genetics and infection mechanisms. Principles and Practice of Infectious Diseases, p. 39, 42. Churchill Livingstone, Philadelphia
28. Fraser, IP, Koziel, H. and Ezekowitz, RA. (1998) The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol, 10, pp. 363-372.
29. Bhole, D. and Stahl, GL. (2003) Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med, 31, p. S97.
30. NatImmune MBL information memorandum: A novel protein replacement for immune therapy and prophylaxis.
31. Miller, ME, Seals, J., Kaye, R. and Levitsky, LC. (1968) A familial, plasma-associated defect of phagocytosis: A new case of recurrent bacterial infections. Lancet, 11, pp. 60-63.
32. Neth, O., Hann, I., Turner, MW and Klein, NJ. (2001) Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet, 358, pp. 614-618.
33. Sutherland, AM, Walley, KR and Russell, JA. (2005) Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med, 33, pp. 638-644.
34. Valdimarsson, H., Stefansson, M. Vikingsdottir, T. et al. (1998) Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand J Immunol, 48, pp. 116-123.
35. Garred, P., Lanng, S. Madsen, HO et al. (2002) Mannose-binding lectin therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol, 33, pp. 201-207.
36. Kahn, SJ, Wleklinski, M. Ezekowitz, RA et al. (1996) The major surface glycoprotein of Trypanosoma cruzi amastigotes are ligands of the human serum mannose-binding protein. Infect Immun, 64, pp. 2649-2656.
37. Green, PJ, Feizi, T. Stoll, MF et al. (1994) Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol, 66, pp. 319-328.
38. Garred, P., Madsen, HO Halberg, P. et al. (1999) Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum, 42, pp. 2145-2152.
39. Santos, IK, Costa, CH Krieger, H. et al. (2001) Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun, 69, pp. 5212-5215.
40. Garred, P., Larsen, F., Madsen, HO and Koch, C. (2003) Mannose-binding lectin deficiency-revisited. Mol Immunol, 40, pp. 73-84.
41. Giraldo, PC, Babula, O. Goncalves, AK et al. (2007) Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol., 109, pp. 1123-1128.
42. Liu, F., Liao, Q. and Liu, Z. (2006) Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet, 92, pp. 43-47.
43. Babula, O., Lazdane, G. Kroica, J. et al. (2005) Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis, 40, pp. 1258-1262.
44. Madan, T., Kaur, S. Saxena, S. et al. (2005) Role of collectins in innate immunity against aspergillosis. Med Mycol, 43, p. S155.
45. Granell, M., Urbano-Ispizua, A. Suarez, B. et al. (2006) Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol, 34, pp. 1435-1441.
46. Roos, A., Bouwman, LH van Gijlswijk-Janssen, DJ et al. (2001) Human IgA activates the complement system via the MBL pathway. J Immunol, 67, pp. 2861-2868.
47. Roos, A., Bouwman, LH Munoz, J. et al. (2003) Functional characterization of the lectin pathway of complement in human serum. Mol Immunol, 39, pp. 655-668.
48. Roos, A., Garred, P. Wildenberg, ME et al. (2004) Antibody-mediated activation of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol, 34, pp. 2589-2598.
49. Selander, B., Martensson, U. Weintraub, A. et al. (2006) Mannan-binding lectin activates C3 and the alternate pathway without involvement of C2. J Clin Invest, 116, pp. 1425-1434.
50. Clardy, J., Fischbach, MA and Walsh, CT. (2006) New antibiotics from bacterial natural products. Nat Biotechnol, 24, pp. 1541-1549.
51. Hiramoto, F., Nomura, N., Furumai, T., Oki, T. and Igarashi, Y. (2003) Apoptosis-like cell death of Saccharomyces cerevisiae induced by a mannose-binding antifungal antibiotic, pradimicin. J Antibiot, 56, pp. 768-772.